NON-HODGKIN'S LYMPHOMA
Clinical trials for NON-HODGKIN'S LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new NON-HODGKIN'S LYMPHOMA trials appear
Sign up with your email to follow new studies for NON-HODGKIN'S LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Four-Pronged attack on Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial is testing a new experimental drug called GNC-035 in adults with non-Hodgkin's lymphoma that has come back or hasn't responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. GNC-035 is a type of antibod…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New 'Living Drug' trial offers hope for tough blood cancers
Disease control Recruiting nowThis is a first-in-human study testing a new personalized cell therapy called CLIC-2201 for adults and children with B-cell blood cancers that have returned or not responded to other treatments. The therapy involves collecting a patient's own immune cells, genetically modifying t…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug combo aims to boost stem cell harvest for cancer patients
Disease control Recruiting nowThis study is testing a new combination of drugs to help collect stem cells from patients with non-Hodgkin's lymphoma. These collected cells are needed for a stem cell transplant, which is a treatment to control the cancer. The trial will compare the new drug combination against …
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE3 • Sponsor: The Affiliated People's Hospital of Ningbo University • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New Four-Target drug tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis early-stage study is testing a new experimental drug called GNC-038 in adults whose non-Hodgkin's lymphoma has come back or hasn't responded to other treatments. The main goals are to find a safe dose and see if the drug can help control the cancer. The drug is a special ant…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New immune therapy trial offers hope for lymphoma patients out of options
Disease control Recruiting nowThis study is testing a new immune-boosting drug called glofitamab, given alone or with another drug (obinutuzumab), for people with B-cell non-Hodgkin's lymphoma that has come back or hasn't responded to prior treatments. The main goals are to find a safe and effective dose and …
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Lab-Trained immune cells take aim at Virus-Linked cancers
Disease control Recruiting nowThis study is testing a new way to treat certain lymphomas linked to the Epstein-Barr virus (EBV). Doctors take a patient's own white blood cells, train them in a lab to recognize and attack EBV-infected cancer cells, and then infuse them back into the patient. The main goals are…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New hope for tough blood cancers: first human trial of experimental pill begins
Disease control Recruiting nowThis is the first study in people testing an experimental oral drug called ABBV-525 for several types of advanced B-cell blood cancers, including lymphoma and leukemia. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it …
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for tough blood cancers: optimized transplant trial seeks to control disease
Disease control Recruiting nowThis study is collecting information on patient outcomes after receiving a cord blood transplant using Memorial Sloan Kettering's optimized procedure. It aims to see how well this standard transplant approach works for adults with high-risk blood cancers like leukemia, lymphoma, …
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New hope for Tough-to-Treat lymphoma: adding a pill to standard chemo
Disease control Recruiting nowThis study is testing if adding a pill called acalabrutinib to standard chemotherapy can help more people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It is for adults who have not yet started any treatment for their lymphoma. Researchers …
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New hope for Tough-to-Treat lymphoma: first human trial begins
Disease control Recruiting nowThis is the first human study of an experimental drug called ABBV-291 for adults with non-Hodgkin's lymphoma that has returned or not responded to at least two prior treatments. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Last-Hope drug offered early to blood cancer patients
Disease control AVAILABLEThis program provides early access to the drug venetoclax for patients with certain blood cancers like leukemia and lymphoma before it is fully approved in their country. It is for patients who have no other suitable treatment options and do not qualify for ongoing clinical trial…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Sponsor: AbbVie • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
Race to shield cancer patients from deadly infections
Prevention Recruiting nowThis trial aims to find the safest and most effective way to prevent serious infections in adults with blood cancers like myeloma, lymphoma, and leukemia. It will directly compare two common prevention strategies: immunoglobulin therapy and antibiotics. The goal is to see which a…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: Monash University • Aim: Prevention
Last updated Mar 30, 2026 14:34 UTC
-
Massive 10,000-Patient study tracks leukemia treatment results
Knowledge-focused Recruiting nowThis study is creating a large registry to collect information about how adult patients with acute lymphoblastic leukemia (ALL) and related blood cancers are diagnosed and treated in real-world settings. Researchers will follow 10,000 participants to track their survival, remissi…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Sponsor: Goethe University • Aim: Knowledge-focused
Last updated Apr 04, 2026 00:20 UTC
-
Major cancer centers launch massive transplant tracking project
Knowledge-focused Recruiting nowThis study collects health information from patients receiving stem cell transplants for various blood cancers and immune disorders. Researchers will track 2,000 patients over time to gather data on survival rates and treatment complications. The goal is to build a comprehensive …
Matched conditions: NON-HODGKIN'S LYMPHOMA
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:15 UTC
-
Global hunt for clues to predict survival in rare skin cancer
Knowledge-focused Recruiting nowThis international study aims to create a better tool to predict survival for people with advanced mycosis fungoides and Sézary syndrome, two rare types of skin lymphoma. Researchers will follow 2,000 patients to collect detailed information about their disease and treatments. Th…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:40 UTC